Offerpad Solutions OPAD 深 沪
等待开盘 09-17 09:30:00 美东时间
3.48
-0.090
-2.52%
华盛通- 最 高3.69
- 今 开3.63
- 成交量 6.18万股
- 最 低 3.45
- 昨 收 3.57
- 总市值 1681.80万
- 52周最高 48.40
- 市盈率 静 --
- 换手率 1.28%
- 52周最低 3.45
- 委 比 68.40%
- 总股本 483.27万
- 历史最高 3145.50
- 量 比 2.10
- 振 幅 6.72%
- 历史最低 3.45
- 每 手 1
- 风险率 10.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Offerpad Solutions adds independent director to strengthen governance
An announcement from Offerpad Solutions ( ($OPAD) ) is now available. On Septem...
09-08 21:50
Offerpad Expands Revolving Credit Capacity to $150 Million
An update from Offerpad Solutions ( ($OPAD) ) is now available. On August 26, 2...
09-01 04:50
Offerpad Solutions Announces Nasdaq Listing Transfer and Repositioning
Offerpad Solutions ( ($OPAD) ) just unveiled an update. On August 18, 2026, Off...
08-19 04:29
Offerpad to transfer listing to Nasdaq from NYSE
Offerpad Solutions (OPAD) on Tuesday said it will transfer the listing of its class A common stock to the Nasdaq Capital Market from the NYSE. The common stock will continue to be listed on the NYSE u...
08-19 04:21
美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
Keefe, Bruyette & Woods Maintains Market Perform on Offerpad Solutions, Lowers Price Target to $4.5
Keefe, Bruyette & Woods analyst Ryan Tomasello maintains Offerpad Solutions (NYSE:OPAD) with a Market Perform and lowers the price target from $5.5 to $4.5.
08-04 22:14
美国线上房产交易平台Offerpad将于8月3日发布第二季度财报
在线房地产平台Offerpad Solutions周二宣布，将于8月3日美股收盘后发布2026年第二季度财务业绩。公司将于当天美国东部时间下午4：30举行电...
07-16 03:24
Offerpad Solutions Announces A 1-For-10 Reverse Stock Split Effective On June 8, 2026
Offerpad Solutions Inc. ("Offerpad" or the "Company") (NYSE:OPAD), a leading tech-enabled real estate solutions company, announced today that it will effect a 1-for-10 reverse stock split (the "Reverse Stock Split") of
06-05 05:39
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Keefe, Bruyette & Woods Maintains Market Perform on Offerpad Solutions, Lowers Price Target to $0.85
Keefe, Bruyette & Woods analyst Ryan Tomasello maintains Offerpad Solutions (NYSE:OPAD) with a Market Perform and lowers the price target from $1 to $0.85.
05-08 01:34
